The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B01 | Antithrombotic agents | |
| 3 | B01A | Antithrombotic agents | |
| 4 | B01AE | Direct thrombin inhibitors | |
| 5 | B01AE07 | Dabigatran etexilate |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.3 g |
| Active Ingredient | Description | |
|---|---|---|
| Dabigatran |
Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| PRADAXA 110mg Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PRADAXA 150mg Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PRADAXA 75mg Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PRADAXA Coated granules | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
